Ax­el Bou­chon starts sign­ing play­ers for a new league of game-chang­ing biotechs

Ax­el Bou­chon is the point man at Bay­er who’s tak­ing a con­cept out­lined on a piece of pa­per back in De­cem­ber and turn­ing it in­to a $335 mil­lion biotech with more than 100 de­vel­op­ment staffers in key lo­ca­tions in the U.S. and Eu­rope. That’s a big task, but it’s on­ly one facet in a much more am­bi­tious life sci­ence game plan he’s quar­ter­back­ing for Bay­er, ramp­ing up 3 to 5 star­tups with fi­nanc­ing rounds stretch­ing from $100 mil­lion to $300 mil­lion or more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER